Derniers articles

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

AbstractBACKGROUND:Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Trials

Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF)

AbstractBackground: Failed kidney transplant is becoming a frequent cause of dialysis initiation. Although studies...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Nephrol Dial Transplant

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

AbstractBACKGROUND:The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Eur J Cancer.

Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score.

AbstractBACKGROUND:About 5% of pancreatic ductal adenocarcinomas are inherited due to a deleterious germline mutation...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : United European Gastroenterol

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...

Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

AbstractBACKGROUND:The incidence of anal squamous cell carcinoma has been increasing markedly in the past few decades....

Posté par : Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

AbstractBACKGROUND:At time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

Letter to editor.LINK

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : European Journal of Cancer

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Trials

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : New England Journal of Medicine

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : Ann Oncol

Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.

BACKGROUND:Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Exp Hematol Oncol

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

BackgroundPatients treated with chemotherapy for microsatellite unstable (MSI) and/or mismatch repair deficient (dMMR)...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Eur J Cancer

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

AbstractBackground The overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancer is a poor...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : BMC Cancer

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Annals of Oncology

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

AbstractBackground: Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : BMC Cancer

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

AbstractTemozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)....

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Endocrine-Related Cancer